Short-read sequencing market projected to reach $17.75 billion by 2030

The Business Research Company says the short-read sequencing market will grow from $7.8 billion in 2025 to $17.75 billion by 2030, driven by genomics research, precision medicine, oncology and rare disease testing. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Short-read sequencing is becoming a core tool in genomics, clinical diagnostics and precision medicine. - The market’s projected climb to $17.75 billion by 2030 signals continued demand for faster, cheaper DNA analysis across healthcare and research. - The growth outlook matters for sequencing vendors, labs, drug developers and health systems building genomics capacity.

What happened: - The Business Research Company released a market study on the global short-read sequencing market. - The report projects the market will rise from $7.8 billion in 2025 to $9.2 billion in 2026. - The company expects the market to reach $17.75 billion by 2030. - The projected growth rate is 17.9% CAGR from 2025 to 2030. - The report was published Aug. 26, 2026, from London. - The company made the report and a sample available online: Download a free sample and View the full report.

The details: - Short-read sequencing, also called next-generation sequencing, produces many short DNA fragments or reads. - The technology is used to analyze genomes and transcriptomes. - The report links recent growth to more genomics research projects. - Lower sequencing costs have also helped expand adoption. - Academic use of next-generation sequencing continues to increase. - Large-scale population sequencing studies are adding demand. - Wider access to sequencing instruments is supporting market growth. - The report says precision medicine adoption will be a major growth driver through 2030. - Sequencing demand in oncology and rare disease applications is increasing. - Clinical diagnostics that use next-generation sequencing are expanding. - Investment in genomics data infrastructure is rising. - AI-driven sequence analysis tools are becoming more common. - The report highlights broader adoption of high-throughput sequencing platforms. - It also points to more cost-effective whole-genome sequencing, deeper bioinformatics pipelines, and faster, more accurate sequencing.

Between the lines: - The market forecast reflects a shift from sequencing as a research tool to sequencing as a clinical and commercial workflow. - Personalized medicine is a key demand signal because it depends on genetic data to match treatments to patients. - The report’s emphasis on AI and bioinformatics suggests software and data infrastructure will be as important as sequencing hardware. - North America’s lead points to mature research and healthcare systems. - Asia-Pacific’s faster expected growth suggests a catch-up phase driven by public investment and broader healthcare access.

What’s next: - The report expects precision medicine, oncology and rare disease testing to keep pushing demand higher through 2030. - Market expansion will likely depend on continued gains in sequencing speed, accuracy and affordability. - More clinical and translational genomics use cases are expected as AI and bioinformatics pipelines mature. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards, hotspots infographics and updated graphics.

The bottom line: - Short-read sequencing is moving deeper into mainstream healthcare, and the market outlook remains strong through the end of the decade.